|
Introduction
Management
of Corporate Collaborations
Academic Research Collaboration Management
Introduction
 Keeping a project on time and
on target requires effort. Sometimes the science is so time consuming that managing the program is forgotten. Deadlines needed for funding and commercialization are missed because no one was focused on keeping the decision making on track.
DNA Bridges®, Inc. will work with your scientists, managing the project so they can focus on what they do best: Science.
Management
of Corporate Collaborations Case Studies
An example of previous experience in facilitating corporate partnerships is demonstrated by the success of the Glaxo-Wellcome and Megabios Corp. (now Valentis, Inc.) partnership leading to the development
of a treatment for cystic fibrosis. This effort has lead to a Phase I/II clinical trials with a gene-based therapeutic for cystic fibrosis.
ISSUE: The product development team had decided to
partner with a vendor to develop one of the individual products needed to commercialize a new family of products. A lot of frustration was growing between the supplier and the development team. The people had not met and had many beliefs and expectations that were not aligned.
SOLUTION: DNA Bridges®, Inc. arranged for the teams to meet and to discuss the project expectation in terms understood by both
business cultures. Changes in staffing were recommended and implemented. Clear communicantion tools were developed: phone calls were followed with written minutes; conference calls were planned in advance and followed up with clearly defined action statements.
BUSINESS IMPACT: The product was launched and continues to exceed customer's expectations. Both business partners are happy with the results.
Academic Research Collaboration Management
DNA Bridges®, Inc.'s experience includes the initiation and oversight of 15 academic collaborations with 10 institutions, resulting in millions
of dollars of research.
Turning basic research into a therapeutic application can be seen by the collaboration between Megabios Corp. (now Valentis, Inc.) and National Jewish Hospital to develop a gene therapy drug for
melanoma.
|
Home
Services
